IP Library Granted Patent US 10,011,857
Granted Patent B2
US 10,011,857 · App. 15/087,201 · Granted Jul 3, 2018

Mannosidases capable of uncapping mannose-1-phospho-6-mannose linkages and demannosylating phosphorylated N-glycans and methods of facilitating mammalian cellular uptake of glycoproteins

Inventors: Kathleen Camilla Telesphore Alida Maria Piens (Ghent, BE); Wouter Vervecken (Landskouter, BE); Albena Vergilieva Valevska (Astene, BE); Gwenda Noëlla Pynaert (Aalter, BE)
Assignee: Oxyrane UK Limited
C12P21/005A61K38/16A61K38/1709C12N9/2402C12N9/2488C12Y302/01024A61K38/00C12Y302/01Y02P20/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,011,857
App. No.
15/087,201
Granted
Jul 3, 2018
Kind
B2
Abstract

The invention provides mannosidases capable of uncapping mannose-1-phospho-6-mannose moieties and demannosylating phosphorylated N-glycans, methods of using such mannosidases, glycoproteins produced using the methods, as well as methods of facilitating mammalian cellular uptake of glycoproteins.

Claims (16)

1. A method for uncapping mannose-1-phospho-6-mannose moieties and demannosylating phosphorylated N-glycans on a glycoprotein, said method comprising:

a) providing said glycoprotein having phosphorylated N-glycans containing said mannose-1-phospho-6-mannose moiety; and

b) contacting said glycoprotein with a single mannosidase that (i) hydrolyzes a mannose-1-phospho-6-mannose moiety to mannose-6-phosphate and (ii) hydrolyzes terminal alpha-1,2 mannose, alpha-1,3 mannose, or alpha-1,6 mannose linkages, wherein said single mannosidase is a Jack Bean mannosidase,

wherein the method is performed in vitro.

2. The method of claim 1 , wherein said glycoprotein is a human protein.

3. The method of claim 1 , wherein said glycoprotein is a pathogen protein, a lysosomal protein, a growth factor, a cytokine, a chemokine, an antibody or antigen-binding fragment thereof, or a fusion protein.

4. The method of claim 3 , wherein said lysosomal protein is a lysosomal enzyme.

5. The method of claim 4 , wherein said lysosomal enzyme is acid alpha glucosidase or alpha galactosidase.

6. The method of claim 1 , wherein said glycoprotein is associated with a lysosomal storage disorder (LSD.

7. The method of claim 6 , wherein said LSD is Fabry's disease, mucopolysaccharidosis I, Farber disease, Gaucher disease, GM1-gangliosidosis, Tay-Sachs disease, Sandhoff disease, GM2 activator disease, Krabbe disease, metachromatic leukodystrophy, Niemann-Pick disease, Scheie disease, Hunter disease, Sanfilippo disease, Morquio disease, Maroteaux-Lamy disease, hyaluronidase deficiency, aspartylglucosaminuria, fucosidosis, mannosidosis, Schindler disease, sialidosis type 1, Pompe disease, Pycnodysostosis, ceroid lipofuscinosis, cholesterol ester storage disease, Wolman disease, Multiple sulfatase deficiency, galactosialidosis, mucolipidosis, cystinosis, sialic acid storage disorder, chylomicron retention disease with Marinesco-Sjögren syndrome, Hermansky-Pudlak syndrome, Chediak-Higashi syndrome, Danon disease, or Geleophysic dysplasia.

8. A method for uncapping mannose-1-phospho-6-mannose moieties and demannosylating phosphorylated N-glycans on a glycoprotein, said method comprising:

a) providing said glycoprotein having phosphorylated N-glycans containing said mannose-1-phospho-6-mannose moiety;

b) contacting said glycoprotein with a single mannosidase that (i) hydrolyzes a mannose-1-phospho-6-mannose moiety to mannose-6-phosphate and (ii) hydrolyzes terminal alpha-1,2 mannose, alpha-1,3 mannose, or alpha-1,6 mannose linkages, wherein said single mannosidase is a Jack Bean mannosidase; and

c) contacting a mammalian cell with said glycoprotein comprising said demannosylated phosphorylated N-glycans, wherein, after said contacting, said glycoprotein is transported to the interior of said mammalian cell,

wherein the method is performed in vitro.

9. The method of claim 8 , wherein said mammalian cell is a human cell.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 30, 2024
From: OXYRANE UK LTD
To: VIB VZW
Reel/Frame 067265/0154 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 31, 2016
From: PIENS, KATHLEEN CAMILLA TELESPHORE ALIDA MARIA; VERVECKEN, WOUTER; VALEVSKA, ALBENA VERGILIEVA; PYNAERT, GWENDA NOELLA
To: OXYRANE UK LIMITED
Reel/Frame 038164/0585 →
Continuity (4)
Division 13876769
Provisional Application 61477014 · Apr 19, 2011
Provisional Application 61387940 · Sep 29, 2010
Related Publication 20160251693A1 · Sep 1, 2016